Granted Patent
B2
US 12,435,309 · App. 17/804,239 · Granted Oct 7, 2025
Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
Inventors:
Ann Marie Leen (Houston, TX); Ulrike Gerdemann (Cambridge, MA); Cliona M. Rooney (Bellaire, TX); Juan F. Vera Valdes (Houston, TX); John R. Wilson (New Brighton, MN)
C12N5/0636A61K39/12A61K39/155A61K39/245A61K40/11A61K40/22A61K40/418A61K40/424A61K40/4266A61K40/4267A61K40/4268A61K40/4269A61K40/427A61K40/4273A61K40/46C12N5/0638A61K2039/54A61K2039/572A61K2239/31A61K2239/38A61K2239/48C12N2501/23C12N2501/2302C12N2501/2306C12N2501/2307C12N2501/2312C12N2501/2315C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
Claims (11)
1. A method of producing a cultured polyclonal population of cytotoxic T-lymphocytes (CTLs) that recognize at least one epitope from each of at least two different tumor antigens, said population comprising CD4+ T-lymphocytes and CD8+ T-lymphocytes, comprising the steps of:
ia) stimulating DCs or PBMCs with at least two libraries of peptides that each represent at least one epitope from each of at least two different tumor antigens to generate antigen presenting cells (APCs) and stimulating T cells with the APCs to generate antigen-specific T lymphocytes; or
ib) stimulating PBMCs with at least two libraries of peptides that each represent at least one epitope from each of at least two different tumor antigens to generate antigen-specific T-lymphocytes; and
ii) culturing the antigen-specific T-lymphocytes in the presence of IL-7 and IL-15 to generate a population of CTLs.
2. The method of claim 1 , wherein the antigen-specific T-lymphocytes are cultured in the presence of IL-7, IL-15, IL-12, and either IL-6 or IL-27.
3. The method of claim 1 , wherein the antigen-specific T-lymphocytes are cultured in a gas permeable vessel.
4. The method of claim 1 , wherein the antigen-specific T-lymphocytes or CTLs are stimulated one or more times by DCs or PBMCs contacted with at least two libraries of peptides that represent the at least two tumor antigens.
5. The method of claim 4 , wherein the one or more stimulations has been performed using DCs and where DCs have been used in the first stimulation.
6. The method of claim 1 , wherein the libraries of peptides were chemically synthesized.
7. The method of claim 1 , wherein the CTLs comprise MHC-restricted CTLs.
8. The method of claim 1 , wherein the peptides in each library overlap in sequence to span at least a part of a tumor antigen.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 26, 2022
From: LEEN, ANN M.; GERDEMANN, ULRIKE; ROONEY, CLIONA; VERA, JUAN
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 060031/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 26, 2022
From: WILSON, JOHN R.
To: WILSON WOLF MANUFACTURING
Reel/Frame 060031/0266 →
Continuity (6)
Provisional Application
61236261
· Aug 24, 2009
References Cited (400)
US 5641628A
· Bianchi
· 1997
[cited by applicant]
US 5843405A
· Middeldorp
· 1998
[cited by applicant]
US 5869453A
· Moss et al.
· 1999
[cited by applicant]
US 5962318A
· Rooney et al.
· 1999
[cited by applicant]
US 6040177A
· Riddell et al.
· 2000
[cited by applicant]
US 6143865A
· Middeldorp
· 2000
[cited by applicant]
US 6274378B1
· Steinman et al.
· 2001
[cited by applicant]
US 6451305B1
· Boussiotis et al.
· 2002
[cited by applicant]
US 6455299B1
· Steinman et al.
· 2002
[cited by applicant]
US 6528307B1
· Herlyn
· 2003
[cited by applicant]
US 6699477B2
· Khanna et al.
· 2004
[cited by applicant]
US 6713053B1
· Bach et al.
· 2004
[cited by applicant]
US 6723695B1
· Burrows et al.
· 2004
[cited by applicant]
US 6821778B1
· Engleman et al.
· 2004
[cited by applicant]
US 6828147B1
· Santoli et al.
· 2004
[cited by applicant]
US 7005131B1
· Steinman et al.
· 2006
[cited by applicant]
US 7638325B2
· June et al.
· 2009
[cited by applicant]
US 7723107B2
· Kirkin et al.
· 2010
[cited by applicant]
US 7745140B2
· June et al.
· 2010
[cited by applicant]
US 7785806B2
· Warren et al.
· 2010
[cited by applicant]
US 7785875B2
· Hwang et al.
· 2010
[cited by applicant]
US 7811581B2
· Middeldorp
· 2010
[cited by applicant]
US 7846446B2
· Cannon et al.
· 2010
[cited by applicant]
US 7951383B2
· Murphy et al.
· 2011
[cited by applicant]
US 7994096B2
· Kem et al.
· 2011
[cited by applicant]
US 8138314B2
· Exley et al.
· 2012
[cited by applicant]
US 8481051B2
· Kuzushima et al.
· 2013
[cited by applicant]
US 8546137B2
· Cannon et al.
· 2013
[cited by applicant]
US 8722401B2
· Groux et al.
· 2014
[cited by applicant]
US 8741642B2
· Manjili et al.
· 2014
[cited by applicant]
US 9115402B2
· Hacohen et al.
· 2015
[cited by applicant]
US 9255243B2
· Wilson et al.
· 2016
[cited by applicant]
US 9963677B2
· Leen et al.
· 2018
[cited by applicant]
US 20020051784A1
· Boussiotis et al.
· 2002
[cited by applicant]
US 20020119121A1
· Vitiello et al.
· 2002
[cited by applicant]
US 20020155108A1
· Barbera-Guillem
· 2002
[cited by applicant]
US 20030148982A1
· Brenner et al.
· 2003
[cited by applicant]
US 20030153073A1
· Rogers et al.
· 2003
[cited by applicant]
US 20030219458A1
· Wang
· 2003
[cited by applicant]
US 20040022761A1
· Banchereau et al.
· 2004
[cited by applicant]
US 20040096457A1
· Huber et al.
· 2004
[cited by applicant]
US 20040106159A1
· Kem et al.
· 2004
[cited by applicant]
US 20050221481A1
· Migliaccio et al.
· 2005
[cited by applicant]
US 20060045883A1
· Molldrem et al.
· 2006
[cited by applicant]
US 20060073126A1
· Shiku et al.
· 2006
[cited by applicant]
US 20060204509A1
· Harty et al.
· 2006
[cited by applicant]
US 20060251664A1
· Kropshofer et al.
· 2006
[cited by applicant]
US 20070003531A1
· Mukherji et al.
· 2007
[cited by applicant]
US 20070048329A1
· Khanna et al.
· 2007
[cited by applicant]
US 20070098734A1
· Cai et al.
· 2007
[cited by applicant]
US 20080260701A1
· Hope
· 2008
[cited by applicant]
US 20090098090A1
· Hart et al.
· 2009
[cited by applicant]
US 20090305408A1
· Chang
· 2009
[cited by applicant]
US 20100035282A1
· Bonini et al.
· 2010
[cited by applicant]
US 20100254958A1
· Letsch et al.
· 2010
[cited by applicant]
US 20110236363A1
· Chang et al.
· 2011
[cited by applicant]
US 20130045491A1
· Unutmaz
· 2013
[cited by applicant]
US 20130115617A1
· Wilson
· 2013
[cited by applicant]
US 20130129713A1
· Rescigno et al.
· 2013
[cited by applicant]
US 20130217122A1
· Kaplan
· 2013
[cited by applicant]
US 20140212398A1
· Reisner et al.
· 2014
[cited by applicant]
US 20150010519A1
· Leen et al.
· 2015
[cited by applicant]
US 20150037297A1
· Terman
· 2015
[cited by applicant]
US 20150044258A1
· Knaus et al.
· 2015
[cited by applicant]
US 20160208216A1
· Vera et al.
· 2016
[cited by applicant]
US 20160215351A1
· Sahin et al.
· 2016
[cited by applicant]
US 20190144826A1
· Leen et al.
· 2019
[cited by applicant]
US 20190264176A1
· Leen et al.
· 2019
[cited by applicant]
US 20200172864A1
· Chiang et al.
· 2020
[cited by applicant]
US 20220152111A1
· Knaus et al.
· 2022
[cited by applicant]
US 20220169986A1
· Leen et al.
· 2022
[cited by applicant]
US 20220257654A1
· Vera Valdes et al.
· 2022
[cited by applicant]
US 20220288119A1
· Vera et al.
· 2022
[cited by applicant]
US 20230028788A1
· Leung et al.
· 2023
[cited by applicant]
CA 2673432A1
· 2008
[cited by applicant]
CN 1877336A
· 2006
[cited by applicant]
CN 101427135A
· 2009
[cited by applicant]
EP 2791163B1
· 2017
[cited by applicant]
JP H09510211A
· 1997
[cited by applicant]
JP 2007511205A
· 2007
[cited by applicant]
JP 2013502235A
· 2013
[cited by applicant]
JP 2013530943A
· 2013
[cited by applicant]
WO 1994002156A1
· 1994
[cited by applicant]
WO 9524217A1
· 1995
[cited by applicant]
WO 1995027722A1
· 1995
[cited by applicant]
WO 1995031208A1
· 1995
[cited by applicant]
WO 1998033888A1
· 1998
[cited by applicant]
WO 0050569A1
· 2000
[cited by applicant]
WO 0142445A2
· 2001
[cited by applicant]
WO 2002077030A2
· 2002
[cited by applicant]
WO 2005028505A2
· 2005
[cited by applicant]
WO 2005035728A2
· 2005
[cited by applicant]
WO 2007097820A2
· 2007
[cited by applicant]
WO 2007099341A1
· 2007
[cited by applicant]
WO 2007121276A2
· 2007
[cited by applicant]
WO 2008025992A2
· 2008
[cited by applicant]
WO 2008073312A2
· 2008
[cited by applicant]
WO 2008073313A2
· 2008
[cited by applicant]
WO 2008148170A1
· 2008
[cited by applicant]
WO 2009053109A1
· 2009
[cited by applicant]
WO 2011028531A1
· 2011
[cited by applicant]
WO 2011024482A1
· 2011
[cited by applicant]
WO 2011146473A1
· 2011
[cited by applicant]
WO 2012062831A1
· 2012
[cited by applicant]
WO 2013088114A1
· 2013
[cited by applicant]
WO 2013088147A1
· 2013
[cited by applicant]
WO 2013088148A2
· 2013
[cited by applicant]
WO 2013119947A1
· 2013
[cited by applicant]
WO 2015075175A1
· 2015
[cited by applicant]
WO 2015110397A2
· 2015
[cited by applicant]
WO 2016073550A1
· 2016
[cited by applicant]
WO 2016073595A1
· 2016
[cited by applicant]
WO 2016073595A8
· 2016
[cited by applicant]
WO 2016154112A1
· 2016
[cited by applicant]
WO 2017049291A1
· 2017
[cited by applicant]
WO 2017203368A1
· 2017
[cited by applicant]
WO 2018005712A1
· 2018
[cited by applicant]
WO 2018052947A1
· 2018
[cited by applicant]
WO 2018055191A1
· 2018
[cited by applicant]
WO 2018232467A1
· 2018
[cited by applicant]
WO 2019050958A2
· 2019
[cited by applicant]
WO 2020198366A1
· 2020
[cited by applicant]
WO 2020227546A1
· 2020
[cited by applicant]
WO 2020255063A1
· 2020
[cited by applicant]
WO 2021021937A1
· 2021
[cited by applicant]
WO 2021034674A1
· 2021
[cited by applicant]
WO 2021133667A1
· 2021
[cited by applicant]
WO 2021189084A1
· 2021
[cited by applicant]
WO 2022025984A1
· 2022
[cited by applicant]
WO 2022064042A1
· 2022
[cited by applicant]
WO 2023159088A1
· 2023
[cited by applicant]
Adamowicz et al., 2019, Interferon-Gamma Elispot Assay: Unique Challenges of Validating Immune Monitoring Assays In a Regulated Environment celerion Translating Science to Medicine pp. 1-4.
[cited by applicant]
Aguayo-Hiraldo et al. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. The Joural of Infectious Diseases; Jul. 2017, 216(2):153-161.
[cited by applicant]
Ando Jun et al “Towards Phase 2/3 Trials for Epstein-Barr Virus (EBV)-Associated Malignancies”, Blood, vol. 118, No. 21, Nov. 2011, p. 1727.
[cited by applicant]
Arasaratnam et al. “Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients” Am J Transplant; Sep. 2018. 18(9): 2238-2249.
[cited by applicant]
Baugh et al. “Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoietic stem cell transplant patients” Curr Opin Infect Dis. Aug. 2018; 31(4): 292-300.
[cited by applicant]
Britten et al., “The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-? ELISPOT assays,” J. Immunol. Methods 259, 95-110, 2002.
[cited by applicant]
Burkett et al, IL-15R expression on CD8+ T cells is dispensable for T cell memory, PNAS Apr. 15, 2003, vol. 100, No. 8.
[cited by applicant]
Carpenter et al., “A side-by-side comparison of T cell reactivity to fifty-nine
[cited by applicant]
Cornish et al, Differential regulation of T-cell growth by IL-2 and IL-15, Blood, Jul. 15, 2006, vol. 108, No. 2.
[cited by applicant]
Decaussin et al., “Expression of BARF1 Gene encoded by Epstein-Barr Virus in Nasopharyngeal Carcinoma Biopsies,” cancer Res. 60, 5584-88, 2000.
[cited by applicant]
Foster et al., “Autologous Designer Antigen-presenting Cells by Gene Modification of T Lymphocytes Blasts With IL-7 and IL-12,” J. Immunother. 30, 506-16, 2007.
[cited by applicant]
Fujita et al., “ Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive Immunotherapy”, J Immunother., 2008, v 31, pp. 665-674.
[cited by applicant]
Fujiwara et al., “Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase”, Blood, 103(8), pp. 3076-3083, Apr. 15, 2004 (Apr. 15, 2004).
[cited by applicant]
Gerdemann et al., “Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation”, Blood, Jan. 3, 2013, vol. 121, No. 1, p. 207-218.
[cited by applicant]
Goon et al, “Human T Cell Lymphotropic Virus (HTLV) Type-1-Specific CD8+ Cells: Frequency and Immunodominance Hierarchy”, The Journal ol Inlectious Diseases, Jun. 15, 2004;189: 2294-2298.
[cited by applicant]
Goon et al., “Human T Cell Lymphotropic Virus Type I (HTLV-I)-Specific CD4+ T Cells: fmmunodominance Hierarchy and Preferential Infection with HTLV-11”, The Journal of Immunology, 2004, 172: 1735-1743.
[cited by applicant]
Halawi et al., “Identification of novel CD8+ T cell epitopes in human herpesvirus 6B U11 and U90”, Immunity, Inflammation and Disease 2015; 3(2): 1 18-131.
[cited by applicant]
Herd et al., “Major Histocompatibility Complex Class I Cytotoxic T Lymphocyte Immunity to Human Metapneumovirus (hMPV) in ndividuals with Previous hMPV Infection and Respiratory Disease”, The Journal ol Inlectious Disea…
[cited by applicant]
Heslop and Leen “T-cell therapy for viral infections” American Society of Hematology; 2013; 2013:342-7.
[cited by applicant]
Huye et al., “Combing mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination,” Mol. Ther. 19, 2239-48, 2011.
[cited by applicant]
International Search Report dated Mar. 23, 2021 issued during examination of International Application No. PCT/US2020/065968.
[cited by applicant]
Janetzki et al., Guidelines for the automated evaluation of Elispot assays 1098-114 | vol. 10 N0.7 | 2015 | Nature Protocols.
[cited by applicant]
Jenkins et al “In Vivo Activation of Antigen-Specific CD4 T Cells” Annu. Rev. Immunol. 2001. 19:23-45.
[cited by applicant]
Jeras et al., “Induction/Engineering, Detection, Selection, and Expansion of Clinical-Grade Human Antigen-Specific CD8+ Cytotoxic T Cell Clones for Adoptive Immunotherapy,” Journal of Biomedicine and Biotechnology, vol.…
[cited by applicant]
Khan et al., “ T Cell Recognition Patterns of Immunodominant Cytomegalovirus Antigens in Primary and Persistent Infection”, The Journal of Immunology, 2007, 178: 4455-4465.
[cited by applicant]
Kim et al., “The ABCs of artificial antigen presentation”, Nature Biotechnology, 22(4), pp. 403-410, Apr. 2004 (Apr. 2004).
[cited by applicant]
Lee et al, HLA A2.1-restricted Cytotoxic T cells Recognizing a Range of Epstein-Barr Virus Isolates through a Defined Epitope in Latent Membrane Protein LMP2, Journal of Virology, Dec. 1993, p. 7428-7435.
[cited by applicant]
Leen et al., “Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation”, Blood, Jun. 27, 2013 x vol. 121, No. 26; pp. 5113-5123.
[cited by applicant]
Leen, A. et al., “Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins For Human CD4+ T-Helper 1 Responses,” Journal of Virology, The American Society for Microbiology, vol. 75, No. 18, p. 8649-8659, …
[cited by applicant]
Leung et al. “Evaluation of cyclin A 1-specific T cells as a potential treatment for acute myeloid leukemia,” Blood Adv, Jan. 28, 2020 (Jan. 28, 2020), vol. 4, pp. 387-397.
[cited by applicant]
Liu et al, IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression and cytotoxicity in CD8+ memory T cells, PNAS Apr. 30, 2002, vol. 99, No. 9.
[cited by applicant]
Meij et al., Int J_ Cancer, 2002, vol. 99, pp. 93-99.
[cited by applicant]
Merlo et al., “The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders,” Haematologica 95, 1769-77, 2010.
[cited by applicant]
Merrick et al., “Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells but impairs early naive cytotoxic pr…
[cited by applicant]
Mitchell Monica L et al: “Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy”, Blood, American Society of Hematology, …
[cited by applicant]
Ngo, “Towards Phase 2/3 Trials for Epstein-Barr Virus (EBV)-Associated Malignancies,” 2011 Graduate Student Symposium of the Graduate School of Biomedical Sciences at Baylor College of Medicine, p. 231, 2011.
[cited by applicant]
Papadopoulou et al. “Activity of broad-spectrum T-cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT” Sci Transl Med. 2014: 6(242).
[cited by applicant]
Paul et al.Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes Journal of Immunological Methods 422 (2015) 28-34. Available online Apr. 7, 2015.
[cited by applicant]
PepMix™ Peptide Pools; pp. 1-13 downloaded Feb. 13, 2021.
[cited by applicant]
Peripheral blood mononuclear cell—Wikipedia; pp. 1-3; downloaded Sep. 3, 2020.
[cited by applicant]
Quintarelli et al., “Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia”, Blood, 112(5), pp. 1876-1885, Sep. 1, 2008 (Sep. 1, 2008).
[cited by applicant]
Ray et al., “Role of Individual Glycoproteins of Human Parainfluenza Virus Type 3 in the Induction of a Protective Immune Response”, Journal of Virologoy, Mar. 1988, vol. 62, No. 3, pp. 783-787.
[cited by applicant]
Redchenko & Rickinson, “Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells,” J. Virol. 73, 334-42, 1999.
[cited by applicant]
Rudolf et al., “Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells,” Cancer Immunol. Immunother. 57, 175-83, Epub 2007.
[cited by applicant]
Seig et al., “Inforection and Immunoregulation of T Lymphocytes by Parainfluenza Virus Type 2”, Proceedings of the National Academy of Sciences of the U.S. A., Jul. 1994, vol. 91, No. 14, pp. 6293-6297.
[cited by applicant]
Suhoski et al., “Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules,” Mol. Ther. 15, 981-88, 2007.
[cited by applicant]
Tan et al, A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers, Journal of Immunology 1999; 162: 1827-1835.
[cited by applicant]
Taylor et al., “Mechanisms of immune suppression by interleukin-10 and transforming growth factor-.beta.: the role of T regulatory cells,” Immunology 117, 433-42, 2006.
[cited by applicant]
Tedcastle et al ., “The Characterization of Monoclonal Antibodies to Human Metapneumovirus and the Detection of Multiple Forms of the Virus Nucleoprotein and Phosphoprotein”, Journal of Medical Virology 84: 1061-1070 (2…
[cited by applicant]
The 23rd Annual Graduate Student Research Symposium of the Graduate School of Biomedical Sciences at Baylor College of Medicine, 2011, p. 231.
[cited by applicant]
Turtle & Riddell, “Artificial antigen presenting cells for use in adoptive immunotherapy,” Cancer J. 16, 374-81, 2010.
[cited by applicant]
Tzannou et al. ““Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients,” Blood Advances, Sep. 3, 2019 (Sep. 3, 2019), vol. 3, No. 17, pp. 2571-2580.
[cited by applicant]
Tzannou et al. “Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy” The Joural of Infectious Diseases; Sep. 2017, 216(6):678-687.
[cited by applicant]
Tzannou et al. “Off-the-Shelf Virus-Specific T cells to Treat BK virus, human herpes virus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation” Jour…
[cited by applicant]
Tzannou et al., “Preventing Stem Cell Transplantation-associated Viral Infections using T-cell Therapy Immunotherapy”, Immunotherapy, Aug. 7, 2015, vol. 7, No. 7, pp. 793-810.
[cited by applicant]
Vasileiuou et al. “Rapid Generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections”, Haematologica; 2020, vol. 105(1):235-243.
[cited by applicant]
Withers et al. “Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program,” Biology of Blood and Marrow Transplantation, Aug. 29, 2018 (Aug. 29, 2018), vol…
[cited by applicant]
Zhu et al. J. Gene. Virology, 2010, vol. 91, pp. 1577-1589.
[cited by applicant]
Tanoue et al., “Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors”, Cancer Research, vol. 77, No. 8, Apr. 15, 2017 (Apr. 15, 2017), US,…
[cited by applicant]
Rosewell Shaw et al., “Armed-Ad Gene Therapy Expressing PD-L1 Minibody Enhances the Anti-Tumor Effect of Adoptively Transferred Chimeric Antigen Receptor T-Cells for Solid Tumor Treatment”, Molecular Therapy, vol. 24, N…
[cited by applicant]
Gottschalk et al., “Harnessing the Immune System to Potentiate Oncolytics”, Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 22, No. 2, Feb. 1, 2014 (Feb. 1, 2014), US, pp. 239-240.
[cited by applicant]
Anonymous. “Combining Oncolytic Adenovirus (OncAd) with Tumor Directed, Adenovirusspecific T-cells for the Treatment of Neuroblastoma: Effects of OncAds on Immunosuppressive Myeloid Cells”, Jan. 1, 2016 (Jan. 1, 2016), …
[cited by applicant]
Sieg et al. “Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 6293-6297, 1994.
[cited by applicant]
2005028505, WO.
[cited by applicant]
2005035728, WO.
[cited by applicant]
2007121276, WO.
[cited by applicant]
2008073313, WO.
[cited by applicant]
2009053109, WO.
[cited by applicant]
2011/028531, WO.
[cited by applicant]
2013088147, WO.
[cited by applicant]
2016/073595, WO.
[cited by applicant]
Bensussan et al. “Detection of membrane-bound HLA-G translated products with a specific monoclonal antibody”,
[cited by applicant]
Binggeli et al., American Journal of Transplantation, 2007, vol. 7, pp. 1131-1139.
[cited by applicant]
Blyth et al., “Bk Vims Specific T Cells Expanded Ex Vivo for Use in Cellular Therapy Show Multiple Antigen Specificity and Polyfunctional THI Responses”, abstract #164, S215.
[cited by applicant]
Blyth et al., “BK Vims-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses”,
[cited by applicant]
Blyth et al., in Blood, (Nov. 20, 2009) vol. 114, No. 22, pp. 962, Meeting Info.: 51st Annual Meeting of the American-Society-of-Hematology, New Orleans, LA, USA. Dec. 5-8, 2009, Amer Soc Hematol.
[cited by applicant]
Calarota et al. “Detection of Epstein-Barr vires-specific memory CD
[cited by applicant]
Can and Karahuseyinoglu, “Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells”,
[cited by applicant]
Chakera et al., Clin Exp. Immunol2011, Sep. 156 (3): 401-409.
[cited by applicant]
Chia, Whay-Kuang, et al; Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatement of Metastic and/or Locally Recurrent Nasopharyngeal Carcinoma; The Am. Society of Gene & Cell Therapy,; Molecular Therapy; …
[cited by applicant]
Dasari et al., “Prophylactic and therapeutic adenoviral vector-based multivims-specific Tcell immunotherapy for transplant patients”,
[cited by applicant]
Dunne et al., “Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-15”, Journal of Immunology, 2001, pp. 3129-3138.
[cited by applicant]
Gaundar et al., “The Generation of Clinical Grade Aspergillus Fumigatus (AF) Specific Immune Cells for Adoptive Immunotherapy”, abstract #168, S216.
[cited by applicant]
Gerdeman et al., Blood, 2009, v.114, Abstract 4083.
[cited by applicant]
Gerdemann et al., “Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associates antigens to treat EBV negative lymphoma”, Molecular Therapy, Nature Publishing Group, GB, vol. 19, No. 12, Dec. 1, 2011, pp. …
[cited by applicant]
Gerdemann et al., “Generation of Multivirus-specific T Cellls to Prevent/treat Viral Infections aftr Allogeneic Hematopoietic Stem Cell Transplant”, Journal of Visualized Experiments, May 2011, vol. 51, e2736, pp. 1-6.
[cited by applicant]
Gerdemann et al., “Multivirus-specific CTL for Adoptive Transfer Using In Vitro Pepmix Stimulation”, Biology Blood Marrow Transplant, online Jan. 28, 2011, p. S216.
[cited by applicant]
Gerdemann et al., “Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host”, Molecular Therapy, vol. 17, No. 9, Sep. 1, 2009, pp. 1616-1…
[cited by applicant]
Gerdemann et al., “Rapidly Generated Multivims-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections”,Am.
[cited by applicant]
Gerdemann et al., “Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections”, Molecular Therapy 2012, vol. 20, No. 8, pp. 1622-1632.
[cited by applicant]
Gerdemann et al., “Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant”, Molecular Therapy…
[cited by applicant]
Geyeregger et al. “Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application” PLoS ONE, 2013, 8(4): e59592.
[cited by applicant]
Hobeika et al., “Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease”, Intl. Society for …
[cited by applicant]
International Preliminary Report on Patentablility mailed Feb. 10, 2014, during prosecution of International Application No. PCT/GB2012/053113.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2010/46505, mailed Oct. 14, 2010.
[cited by applicant]
Jeffes Ill et al. “Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enchancement of MAK lytic activity and cytokine production by PHA an…
[cited by applicant]
Jennes et al., “Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15 the Amplispot assay” Journal of Immunological Methods, 2002, vol. 270, pp…
[cited by applicant]
Kedl et al; “T Cells Compete for Antigen-bearing Antigen-presenting Cells”; J.P. Med.—The Rockfeller University Press—vol. 192, No. 8, Oct. 16, 2002.
[cited by applicant]
Kedl et al; “T Cells Down-Modulate Peptide-MHC Complexes on APCs in vivo”; Published online: Dec. 3, 2001, DOI: 10.1 038/ni/742; 2002 Nature Publishing Group.
[cited by applicant]
Khanna et al., Blood, Jul. 2011, vol. 118, No. 4, pp. 1121-1131.
[cited by applicant]
Lapteva and Vera “Optimization Manufacture of Virus- and Tumor-Specific T Cells”, Stem Cells International, Apr. 26, 2011, vol. 2011, pp. 1-8.
[cited by applicant]
Leen et al., “Cytotoxic lymphocyte (CTL) therapy for the treatment of EBV negative tumors”, Abstract, International Society for Cell and Gene Therapy of Cancer Annual Meeting held in Cork, Ireland, presented Sep. 4, 200…
[cited by applicant]
Leen et al., “Identification of hexon-specific CD4 and CDS T-cell epitopes for vaccine and immunotherapy,”
[cited by applicant]
Leen et al., “Overcoming antigenic competition to produce rnultispecific cytotoxic T lymphocyte lines for adoptive transfer,” Poster, 6th Annual Dan L. Duncan Cancer Center Symposium, Baylor College of Medicine, Feb. 20…
[cited by applicant]
Leen et al., Nature Medicine, 2006, vol. 12, No. 10, pp. 1160-1166.
[cited by applicant]
Liao et al., “Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes”, M…
[cited by applicant]
Lim et al. Journal of Translational Medicine 2009, vol. 7:72, pp. 1-11.
[cited by applicant]
Itoh et al., Nishinihon J of urology, 1998, v.60 pp. 185-190.
[cited by applicant]
Maecker et al., Journal of Immunological Methods, 2001, vol. 55, pp. 27-40.
[cited by applicant]
Montes et al., “Optimum in vitro expansion of human antigen-specific CD8
[cited by applicant]
Morandi et al., “ Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL that Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic Implications”, Neoplasia, Oct. 1, 2006, vol.…
[cited by applicant]
Muftuoglu et al., “Use of Expanded Allogeneic Third Party BK Vims Specific Cytotoxic C6. T Cells to Target Progressive Multifocal. Leukoencephalopathy”,Am.
[cited by applicant]
Na et al., “Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy” Blood, 2007, vol. 110, p. 2973.
[cited by applicant]
Nair et al., “Induction of tumor-specific cyototoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells”, Annals of Surgery, Apr. 1, 2002, vol. 235, No. 4, pp. 540-549.
[cited by applicant]
Olson et al., “Efficacy of Third Party BK Vims (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial”,
[cited by applicant]
Ramaswami et al., Clin Vaccine Immunol, Published on line Mar. 2, 2011, vol. 18, No. 5 815-824.
[cited by applicant]
Suneetha et al., Journal of Immunological Methods, 2009, vol. 342, No. 1-2, pp. 33-48.
[cited by applicant]
Tekkatte, Chandana, et al;““Humanized” Stem Cell Culture Techniques: The Animal Serum Controversy”; Stem Cells Int'l, vol. 2011; Article ID 504723; 14 pgs; Nov. 9, 2010.
[cited by applicant]
Testa et al: “MHC Class I-Presented T Cell Epitopes Identified by Immunoproteomics Analysis Are Targets for a Cross Reactive Influenza-Specific T Cell Response”, PLOS ONE, vol. 7, No. 11, Nov. 7, 2012 (Nov. 7, 2012), p.…
[cited by applicant]
Trivedi et al., “Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy”, Blood, Apr. 1, 2005, vol. 105, No. 7, pp. 2793-2794.
[cited by applicant]
Van MONTFOORT et al., “Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity”, PNAS, Apr. 21, 2009, vol. 106, No. 16, pp. 6730-6735.
[cited by applicant]
Vella et al., “Cytokine-induced survival of activated T cells in vitro and in vivo”, Proc. Natl. Acad. Sci. USA 95, Immunology, Mar. 1998, vol. 95, pp. 3810-3815.
[cited by applicant]
Vera, Juan F., et al; “Accelerated Production of Antigen-Specific T-cells for Pre-Clinical and Clinical Applications using Gas-Permeable Rapid Expansion Cultureware (G-Rex)”; Journal of Immunotherapy, Apr. 2010, vol. 33…
[cited by applicant]
Y E Z, et al; In Vitro expansion and Charcterization of Dendritic Cells Derived from Human Bon Marroe CD34+ Cells; Bone Marrow Transpaln, 1996, v 18. 997-1008.
[cited by applicant]
Zerlik et al., Blood, 2006, v.108 pp. 3865-3870.
[cited by applicant]
Ahmed et al., “Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies,” Viruses 12(3):254, pp. 1-15 (2020).
[cited by applicant]
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition, Business Wire, Sonia Choi, AlloVir, Dec. 10, 2022, 3 pages.
[cited by applicant]
Amary et al., “Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma,” Modern Patho…
[cited by applicant]
Anonymous: “AlloVir”, “2 Posoleucel (Viralym-M, ALVR105): A multi-virus specific T cell Therapy (VST) targeting five devastating viral pathogens,” Jan. 18, 2022 (Jan. 18, 2022), XP093010987, Retrieved from the Internet:…
[cited by applicant]
Anthony et al., “Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukemia and lymphoma,” Bone Marrow Transplant 21:441-446, 1998.
[cited by applicant]
Arons et al., “Prame Expression in Hair Cell leukemia,” Leukemia Research, New York, NY US 32(9):1400-1406 (2008).
[cited by applicant]
Ben-Sasson et al., IL-1 acts directly on CD4 T cells to enhance their; antigen-driven expansion and differentiation, PNAS 106(17)7119-7124 (2009).
[cited by applicant]
Boer et al., “Extensive early apoptosis in frozen thawed CD34+ stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplant,” Bone marrow Transplant 29:24…
[cited by applicant]
Bollard et al., “The generation and characterization of LMP2-specific CTL for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease,” J. Immunother. Jul.-Aug. 2004; 27(4):317-27.
[cited by applicant]
Carrasco et al., “Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells,” The Journal of Immunology 180(5):3585-3593 (2008).
[cited by applicant]
Carrum et al., “Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells”, Blood, American Society of Hematology US, vol. 132, Nov. 29, 2018 (Nov. 29, 2018), p. 1685.
[cited by applicant]
Cha et al., “IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo ,” Breast Cancer Res Treat. Jul. 2010, pp. 1-22.
[cited by applicant]
CMD-003 / Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (CITADEL), Cell Medica, Sep. 23, 2013, https://clinicaltrials.gov/ct2/show/NCT01948180.
[cited by applicant]
Diao et al., “Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019,” Front. Immunol. 11:827, pp. 1-7 (2020).
[cited by applicant]
Dienz and Rincon, “The Effects of IL-6 on CD4 T Cell Responses,” Clin Immunol. Jan. 2009; 130(1): 27-33.
[cited by applicant]
Fast et al., “Potential T-cell and B-cell Epitopes of 2019-nCOV,” BIOrXIV, pp. 1-20 (2020).
[cited by applicant]
Grifoni et al., “A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to Sars CoV-2,” Cell Host & Microbe 27(40):671-680 (2020).
[cited by applicant]
Hemmer et al., “Minimal peptide length requirements for CD4+ T cell clones-implications for molecular mimicry and T cell survival,” International Immunology, vol. 12, No. 3, pp. 375-383 (2000).
[cited by applicant]
Herd et al: “ Cytotoxic T-Lymphocyte Epitope Vaccination Protects against Human Metapneumovirus Infection and Disease in Mice”, Journal of Virology, Feb. 2006, vol. 80, No. 4, p. 2034-2044.
[cited by applicant]
Hunder et al., “Treatment of Metastatic Melanoma with Autologous CD4+ t Cells Against NY-ESO-1,” New England Journal of Medicine 358(25):2698-2703 (2008).
[cited by applicant]
Jacobs et al., “Lab. Investigation—Human/Animal Tissue Selective Cancer-Germline Gene Expression in Pediatric Brain Tumors,” J Neurooncol, pp. 273-280 (2008).
[cited by applicant]
Joshi, Shantaram et al., “Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics,” Blood 98(6):1963-1970 (2001).
[cited by applicant]
Keirnan et al., “PepMix™ Peptide Pools for Clinical Applications: T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant,” JPT Peptide Technologies (2012), 2 pages.
[cited by applicant]
Kelly-Rogers et al. Activation-Induced Expression of CD56 by T Cells Is Associated With a Reprogramming of Cytolytic Activity and Cytokine Secretion Profile In Vitro. Human Immunology 67, 863-873 (2006).
[cited by applicant]
Kikuta, Hideaki, “3. Human Metapneumovirus” Viruses, 2006, vol. 56, No. 2,p. 173-182.
[cited by applicant]
Kindt et al., “Protective Role of the Inhibitor of Apoptosis Protein, Survivin, in Toxin-Induced Acute Renal Failure,” The FASEB Journal, Federation of American Societies for Experimental Biology, US 22(2):510-521 (2008…
[cited by applicant]
Koch CP, Perna AM, Pillong M, Todoroff NK, Wrede P, et al. (2013) Scrutinizing MHC-1 Binding Peptides and Their Limits of Variation. PLoS Comput Biol 9(6): el 003088, 9 pages.
[cited by applicant]
Kumar et al., “Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCOV) and SARS coronavirus (SARS-CoV),” Virusdisease 31(1):13-21 (2020).
[cited by applicant]
Leen et al., “Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells,” J Immunother. Jan. 2007:30(1): 96-107.
[cited by applicant]
Li et al., “T Cell Responses to Whole SARS Coronavirus in Humans,” The Journal of Immunology 181(8):5490-5500 (2008).
[cited by applicant]
Mielcarek et al., “Suppression of Alloantigen-Induced T-Cell Proliferation by CD14+ Cells Derived From Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells,” Blood, vol. 89, No. 5 (Mar. 1),…
[cited by applicant]
Nawa et al., “G-CSF reduces IFN-g and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function,” Bone Marrow Transplantation (2000) 25, 1035-1040.
[cited by applicant]
Nelson et al., “Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients,” Blood advances, pp. 5745-5754 (Nov. 20, 2020).
[cited by applicant]
Parks et al., “Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS),” Handbook of Experimental Immunology, Chapter 29, DM Weir (ed), Blackwell Scientific Publications, MA, 1986, xx pages.
[cited by applicant]
PepTivator® CMV pp65—premium grade, MACS and Peptivator, Miltenyi Biotech GmbH 2013, 4 pages.
[cited by applicant]
Professor Kronenberg Declaration filed in EP 12815750 Opposition on May 15, 2019, 75 pages.
[cited by applicant]
Reyes et al., “Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response,” British Journal of Cancer (1999) 80(1/2):229-235 (1999).
[cited by applicant]
Rooney and Leen, “Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials,” Molecular Therapy-Nucleic Acids (2012) I, e55, 4 pages.
[cited by applicant]
Dadwal et al., “Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Ce11 Therapy, for the Prevention of Viral Infections Post-Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Results from an Open-Labe…
[cited by applicant]
Schmid et al., “Dead Cell Discrimination with 7-aminoactinomycin Din Combination with Dual Colour Immunofluorescence in Single Laser Flow Cytometry,” Cytometry 13:204-208 (1992).
[cited by applicant]
Schnittger et al., in Blood, CBL Mutations Are Correlated with CMML, Frequently Associated with RUNX1 but Mutually Exclusive of JAK2V617F Mutations, Blood114(22):962, 2 pages (Nov. 20, 2009).
[cited by applicant]
Sili et al., “Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cells for adoptive immunotherapy,” J. Immuother. May-Jun. 2003: 26(3): 241-256.
[cited by applicant]
Song et al., “Detection of MAGE and SSX Gene Expressions by RT-nested PCR Using Common Primers in Head and Neck Cancer,” Clinical and Experimental Otorhinolaryngology 1(2):97-102 (2008).
[cited by applicant]
Teague et al., “Interleukin-IS rescues tolerant cos+ T cells for use in adoptive immunotherapy of established tumors,” Nature Medicine 12(3):335-341 (2006).
[cited by applicant]
Thevarajan et al., “Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19,” Nature Medicine 26(4):453-455 (2020).
[cited by applicant]
Tung et al., “Modern Flow Cytometry: A Practical Approach,” Clin Lab Med 27(3):453 (2007), 15 pages.
[cited by applicant]
Tzannou and Leen; Accelerating immune resconstitution after hematopoietic stem cell transplantation: Clinical & Translational Immunology 3:e11, pp. 1-10 (2014).
[cited by applicant]
Vasileiou et al., “Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19,” Transplantation and Cellular Therapy 27, 3S, S1-S488, 3 pages (2021).
[cited by applicant]
Zhou et al., Either IL-2 or IL-12 Is Sufficient to Direct Thi Differentiation by Nonobese Diabetic T Cells1, The Journal of Immunology, 2003, 170:735-740.
[cited by applicant]
Gerdemann et al., “Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections aftr Allogeneic Hematopoietic Stem Cell Transplant”, Journal of Visualized Experiments, May 2011, vol. 51, e2736, pp. 1-6.
[cited by applicant]
_EEN et al., “Identification of hexon-specific CD4 and CDS T-cell epitopes for vaccine and immunotherapy,” Journal of Virology, 82(1):546-554, 2008.
[cited by applicant]
Aguayo-Hiraldo et al: “Adoptive T-Cell Therapy to Prevent and Treat Parainfluenza Virus 3 (PIV-3) Infections Post Hematopoietic Stem Cell Transplant (HSCT)”, Biology of Blood and Marrow Transplantation, vol. 22, No. 3, …
[cited by applicant]
Falsey, Ann “Current management of parainfluenza pneumonitis in immunocompromised patients : a review”, Infection and Drug Resistance, Jan. 1, 2012 (Jan. 1, 2012), p. 121.
[cited by applicant]
Fu et al., Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization, Journal of virology, 1997, 04 months, vol. …
[cited by applicant]
Fuji et al, “Adoptive immunotherapy with virus-specific T cells”, Best Practice & Research Clinical Haematology, vol. 24, No. 3, 2011, pp. 413-419.
[cited by applicant]
Ito Yasuhiko, et al., Antigenic Structures, vol. 39, No. 1, pp. 1989, No. 29, p. 29-45.
[cited by applicant]
Johnstone C et al., “Relevance of viral context and diversity of antigen—processing routes for respiratory syncytial virus cytotoxic T-lymphocyte epitopes”, The Journal of general virology, 2008, 09 months, vol. 89, p. …
[cited by applicant]
Mao et al. “Inhibition of human parainfluenza virus type 3 infection by novel small molecules”, Antiviral Research, vol. 77, No. 2, Oct. 2, 2007 (Oct. 2, 2007), pp. 83-94, Elsevier BV, NL.
[cited by applicant]
Melendi et al., Mapping and Characterization of the Primary and Anamnestic H-2 d-Restricted Cytotoxic T-Lymphocyte Response in Mice against Human Metapneumovirus, Journal of Virology, vol. 81, No. 20, Oct. 2007, pp. 114…
[cited by applicant]
Zavala-Vega et al., “Role of Epstein-Barr Virus in Glioblastoma”, Crit Rev Oncog, 2019 , vol. 24, pp. 307-338.
[cited by applicant]
Zhong W et al., Genome-45144, Wide characterization of a viral cytotoxic T lymphocyte epitope repertoire, The Journal of biological chemistry ,2003—vol. 278, No. 46, p. 45135, 05 months, 09 months.
[cited by applicant]
Dadwal, Sanjeet et al., Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-CeLL Therapy, for the Prevention of Viral Infections Post-Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Results from an O…
[cited by applicant]
Dadwal, Sanjeet et al., “Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-CeLL Therapy, for the prevention of Viral Infections Post-Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Results from an …
[cited by applicant]
Diao et al: “Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)”, medRxiv, Feb. 20, 2020 (Feb. 20, 2020).
[cited by applicant]
EP Search Report dated Apr. 4, 2023 cited in related EP Appl. No. 20777790.5.
[cited by applicant]
EP Search Report dated dated Oct. 16, 2019 cited in related EP Appl. No. 19178235.8.
[cited by applicant]
EP Search Report dated Feb. 7, 2013 cited in related EP Appl. No. 10814245.6.
[cited by applicant]
EP Search Report dated Jul. 20, 2015 in related EP Appl. No. 13746524.1.
[cited by applicant]
EP Search Report dated Mar. 20, 2019 during examination of in related EP Appl. No. 16847545.7.
[cited by applicant]
EP Search Report dated May 21, 2021 cited in related EP Appl. No. 21160943.
[cited by applicant]
EP Search Report dated Oct. 10, 2022 cited in related EP Appl. No. 22166731.
[cited by applicant]
EP Search Report dated Sep. 27, 2016 in related EP Appl. No. 16180607.0.
[cited by applicant]
Hasskarl et al “Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft”, Bone Marrow Transplantation, vol. 47, No…
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued for Application No. PCT/GB2012/053113, dated Feb. 10, 2014.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/044080, dated February 1. 2022.
[cited by applicant]
International Preliminary Report on Patentability issued by the International Searching Authority for Application No. PCT/US2016/052487, dated Mar. 20, 2018.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/GB2012/050896 dated Jun. 17, 2014.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/GB2012/053114, dated Jun. 17, 2014.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2010/025209, mailed Sep . 9, 2011.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2013/025342, dated Aug. 12, 2014.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2020/024726, dated Septemeber 28, 2021.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2020/065968, dated Jun. 28, 2022.
[cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2021/016266, dated Jan. 31, 2023.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/IB2022/061291, dated Mar. 29, 2023.
[cited by applicant]
International Search Report and Written Opinion dated Aug. 10, 2012 in PCT/GB2012/050896.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2020/044080, dated Oct. 28, 2020.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2010/025209, mailed Jul. 14, 2010.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2016/052487, dated Dec. 19, 2016.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/024726, dated Jun. 19, 2020.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2021/016266, dated Jun. 4, 2021.
[cited by applicant]
International Search Report by the International Searching Authority for Application No. PCT/GB2012/053113, dated Mar. 26, 2013.
[cited by applicant]
International Search Report issued in International Application No. PCT/GB2012/053114, dated Jul. 15, 2013.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/025342, dated Aug. 11, 2013.
[cited by applicant]
International Search Report mailed Jun. 29, 2021 during examination of International Application No. PCT/US2021/070291.
[cited by applicant]
Olson et al., “Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation,” J Clin Oncol 39:2710-2719 (2021).
[cited by applicant]
Peggs et al “Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation”, Clinical Infectious Diseases, vol. 52,…
[cited by applicant]
Samuel et al “CMV-reactive T cells can be isolated from G-CSF mobilised peripheral blood apheresates”, Blood, vol. 116, No. 21, Nov. 19, 2010 (Nov. 19, 2010).
[cited by applicant]
Samuel et al “Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function”, British Journal of Haematology, vol. 160, No. 1, Oct. 9, 2012 (Oct.…
[cited by applicant]
Wing et al., “An Improved Method for the Detection of Cell Surface Antigens in Samples of Low Viability using Flow Cytometry,” J Immunol Methods 126: 21-27 1990.
[cited by applicant]
Written Opinion issued in International Application No. PCT/US2013/025342, dated Apr. 11, 2013.
[cited by applicant]
Na et al., Human bone marrow as a source of multifunctional CMV-specific CD4+T cells for adoptive cell therapy 11 , Blood, American Society of Hematology, US, vol. 110, No. 11 Part I, Nov. 16, 2007 (Nov. 16, 2007), p. 8…
[cited by applicant]
Pfeiffer T et al: “Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting”, Clinical Cancer Research, vol. 29, No. 2, Jan. 1…
[cited by applicant]
Vasileiou S et al: “Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections”, Blood, vol. 132, No. Suppl. 1, 3332, Nov. 29, 2018 (Nov. 29, 2018), XP08659271…
[cited by applicant]
Vasileiou S et al: “Rapid Generation of Multivirus-Specific T Lymphocytes for the Prevention and Treatment of Respiratory Viral Infections”, Biology of Blood and Marrow Transplantation, vol. 25, No. 3, 544, Mar. 2019 (M…
[cited by applicant]
Tzannou, Ifigenia, et al. “Adoptive T-cell therapy to prevent and treat human metapneumovirus (hMPV) infections post hematopoietic stem cell transplant (HSCT).” Biology of Blood and Marrow Transplantation 21.2 (Jan. 2, …
[cited by applicant]
Leen, Ann M., Helen E. Heslop, and Malcolm K. Brenner. “Antiviral T-cell therapy.” Immunological reviews 258.1 (Nov. 2, 2014): 12-29.
[cited by applicant]
Qian et al. “Curative or pre-emptive adenovirus-specific T-cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinic…
[cited by applicant]
O'Reilly et al. “Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections”, Bone Marrow Transplantation, vol. 51, pp. 1163-1172, 2016.
[cited by applicant]
Eiz- Vesper et al. “Adoptive T-cell immunotherapy from third-party donars: charcterization of donors and set up of a T-cell donor registry”, Frontiers in Immunology, vol. 3, 28, 2013.
[cited by applicant]
Wang, X. and Rivière, I., “Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies”, Cancer Gene Therapy, 22, pp. 85-94, Feb. 27, 2015.
[cited by applicant]
Leen, A.M. et al., “Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals”, Nature Medicine, 12, pp. 1160-1166, Sep. 24, 2006.
[cited by applicant]
Caruso et al., “Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation,” Cytometry. Jan. 1, 1997;27(1):71-76.
[cited by applicant]
Clancy et al., “Cytomegalovirus (CMV) PP65 Specific T Cells Expanded from Mobilised Peripheral Blood Stem Cell PBSC) Collections for Prophylactic Adoptive Immunotherapy,” Biology of Blood and Marrow Transplantation, 201…
[cited by applicant]